“According to the data We've noticed from the TRIDENT-1 demo, repotrectinib has the possible to be a fresh conventional of care choice for patients with locally Sophisticated or metastatic ROS1 fusion-beneficial lung cancer.”At a similar conference, write-up hoc analyses from Clarity's tau-PET substudy indicated that, among contributors who sta